AI Engines For more Details: Perplexity Kagi Labs You
Skin and Soft Tissue Infections: Linezolid is effective in treating skin and soft tissue infections caused by susceptible bacteria, including cellulitis, infected wounds, and abscesses.
Pneumonia: It is used to treat community-acquired pneumonia and nosocomial pneumonia (hospital-acquired pneumonia) caused by susceptible organisms.
Complicated Skin and Soft Tissue Infections (cSSTIs): Linezolid is indicated for complicated skin and soft tissue infections, such as diabetic foot infections, post-surgical wound infections, and infected ulcers.
Vancomycin-Resistant Enterococcus faecium (VRE) Infections: Linezolid is active against vancomycin-resistant Enterococcus faecium infections, including complicated skin and soft tissue infections and bacteremia.
Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: It is effective against infections caused by methicillin-resistant Staphylococcus aureus, including skin and soft tissue infections, pneumonia, and bloodstream infections.
Intra-abdominal Infections: Linezolid may be used in the treatment of intra-abdominal infections caused by susceptible organisms.
Central Nervous System Infections: In some cases, linezolid is used to treat central nervous system infections, such as meningitis, caused by susceptible bacteria.
Adverse Effects: Common side effects associated with linezolid include nausea, vomiting, diarrhea, headache, and dizziness. Long-term use may be associated with reversible myelosuppression (reduced bone marrow function), including thrombocytopenia (low platelet count), anemia, and leukopenia (low white blood cell count). Rare but serious adverse effects include serotonin syndrome, peripheral neuropathy, and lactic acidosis.
Interaction with Serotonergic Drugs: Linezolid has the potential to interact with serotonergic medications, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and certain opioids, leading to serotonin syndrome.
Resistance: Resistance to linezolid is a concern, although it remains relatively low compared to other antibiotics. Monitoring for resistance and prudent antibiotic use are essential to prevent the development of resistant bacterial strains.
(anozilad, antizolid, arlid, arlin, averozolid, dilizolen, entavar, grampolid, grampolyve, gramposimide, grampoxid, lidobact, linez, linezolid accord, linezolid amneal, linezolid betapharm, linezolid farmaprojects, linezolid fresenius kabi, linezolid gnp, linezolid hetero, linezolid kabi, linezolid mylan, linezolid pfizer, linezolid pliva, linezolid polpharma, linezolid richet, linezolid sandoz, linezolid teva, linezolid zentiva, linezolida teva, linezone, linid, linosept, linozid, linxyd, linzolid, linzowin, litrecan, livegramide, lizbid, lizemox, lizolid, lizoliden, lizomac, lizomed, lizorex, lizox, lorezogram, lynvox, lynz, natlinez, pneumolid, ralinz, respenzo, synzolid, voxazoldin, zenix, zifi-turbo, zizolid, zodlin, zolinid, zyvox, zyvoxam, zyvoxid)
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Enterococcus faecium | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| species | Streptomyces fradiae | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 4 | 1 | Staphylococcus aureus | species | Decreases |
| 3 | 0 | Bacteroides fragilis | species | Decreases |
| 3 | 0 | Escherichia coli | species | Decreases |
| 3 | 0 | Enterococcus faecium | species | Decreases |
| 2 | 3 | Staphylococcus | genus | Decreases |
| 2 | 0 | Nocardia | genus | Decreases |
| 2 | 0 | Bacteroides ovatus | species | Decreases |
| 2 | 0 | Bacteroides uniformis | species | Decreases |
| 2 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 2 | 0 | Clostridioides difficile | species | Decreases |
| 2 | 0 | Clostridium perfringens | species | Decreases |
| 2 | 0 | Enterocloster bolteae | species | Decreases |
| 2 | 0 | Phocaeicola vulgatus | species | Decreases |
| 2 | 0 | Roseburia intestinalis | species | Decreases |
| 2 | 0 | Agathobacter rectalis | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 1.9 | 0.9 | 1.11 |
| ADHD | 5.2 | 0.6 | 7.67 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 5.1 | 3.4 | 0.5 |
| Allergies | 9.1 | 4.4 | 1.07 |
| Allergy to milk products | 3 | 1.6 | 0.88 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 7.5 | 6.8 | 0.1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.3 | 1.9 | 1.26 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.217 ]